In Brief: GSK Sales Drop; FTC Bans Firm From U.S. Market; FDA Warning Letters

This article was originally published in The Tan Sheet

28 Jul 2014
News

Executive Summary

GSK consumer sales drop 4%; Canadian firm banned from weight loss market; basic labeling failures triggers FDA warning letter; claims make Puna Noni products drugs; FDA finds another tainted supplement; and study shows Herbalife is not pyramid scheme.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Consumer United States Strategy

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS107061

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS107061

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

In Brief: GSK Sales Drop; FTC Bans Firm From U.S. Market; FDA Warning Letters

News

Executive Summary

Related Content

Industry Suggests Increase In Spiked Supplements Reflects FDA Investment In Testing, Targeted Selection

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert